About Event

What Can You Expect at the Premier Covalent Forum in 2026?

Returning for Its 4th Year, the Covalent Drug Discovery Summit Meets a Pivotal Moment

With covalent drug discovery moving from a high-risk concept to a clinically validated modality, the race is on to deliver safer, more selective, and translatable covalent therapeutics. As advances in covalent inhibitor design, chemoproteomics, novel warheads, and non-cysteine targeting continue to expand the druggable landscape, organizations are increasingly focused on successful clinical translation.

The 4th Covalent Drug Discovery & Development Summit brings together industry leaders to share cutting-edge case studies and end-to-end covalent drug development strategies, spanning early discovery, target engagement, translational science, and clinical progression.

Expect expert-led sessions, real-world translational insights, and meaningful networking designed to help you overcome selectivity and safety challenges, optimize covalent screening and discovery workflows, and confidently progress covalent candidates from design through to first-in-human studies.

Download the Agenda

Unmissable Event Highlights

Advance Precision Covalent Design Strategies

Discover how Dana-Farber, BMS, and Leiden University are expanding the covalent toolbox through novel warheads, non-cysteine targeting, and electrophile profiling. Learn how integrating structural biology and chemoproteomics is enhancing selectivity, optimizing reactivity, and enabling compounds to successfully progress through in vivo and IND-enabling stages.

Unlock New Biology with Covalent Modalities

Explore how Dana-Farber, Talus Bio, and Dunad Therapeutics are applying covalent strategies to transcription factors, deubiquitinases, and dynamic proteins. Learn how targeting novel residues and developing CNS-penetrant compounds are expanding beyond cysteine and classical inhibition to unlock previously undruggable biology.

Bridge the Gap from Discovery to First-in-Human

Gain end-to-end translational insights from Biogen, Lilly, and Antares Therapeutics. Explore how leading teams are integrating kinact/KI, PK/PD, and safety data to improve decision-making, guide dose selection, and de-risk progression, enabling more confident advancement of covalent candidates into early clinical trials.

Optimize Discovery with Next-Gen Screening & AI

Learn from BridGene, Frontier Medicines, Pfizer, and Axiom Therapeutics how advanced screening platforms, kinetic assays, and AI-driven modelling are transforming hit identification. Discover how proteome-wide approaches and integrated datasets are reducing off-target risk and accelerating high-confidence decision-making.